Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

被引:12
|
作者
Ramos, Guilherme P. [1 ]
Stroh, Gregory [1 ]
Al-Bawardy, Badr [2 ]
Faubion, William A. [2 ]
Papadakis, Konstantinos A. [2 ]
Escalante, Patricio [3 ]
机构
[1] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[3] Mayo Clin, Ctr TB, Dept Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA
关键词
anti-TNF therapy; biologic therapy; Crohn's disease; inflammatory bowel diseases; latent tuberculosis infection; tuberculosis; ulcerative colitis; TUMOR-NECROSIS-FACTOR; GAMMA RELEASE ASSAYS; RHEUMATOID-ARTHRITIS; OPPORTUNISTIC INFECTIONS; MINIMIZING TUBERCULOSIS; ACTIVE TUBERCULOSIS; PRACTICE GUIDELINES; KOREAN PATIENTS; CROHNS-DISEASE; SKIN-TEST;
D O I
10.1093/ibd/izy133
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Treatment for latent tuberculosis infection (LTBI) is of particular concern in patients with inflammatory bowel disease (IBD) initiating biologic therapies to prevent tuberculosis (TB) reactivation. This study aimed to evaluate the effectiveness of LTBI treatment in IBD patients receiving biologic therapy. Methods: There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016. The primary outcome was tuberculosis reactivation after completion of LTBI treatment. Results: Three-hundred twenty-nine IBD patients were identified, and 35 (27 Crohn's disease; 8 ulcerative colitis) met the study inclusion criteria. The mean age was 38.3 years, and 68.6% were male. The most common LTBI treatment regimen was isoniazid (INH) for 9 months (74%). Biologic therapies used were infliximab (40%), adalimumab (29%), vedolizumab (20%), and certolizumab pegol (11%). Combination therapy with an immunomodulator was administered in 57% of cases. The median time from initiation of LTBI treatment to biologics was 43 days. The mean duration of follow-up was 2.9 years. The estimated median annual risk of TB reactivation without treatment was 0.52% by a prediction formula. Only 1 patient taking adalimumab monotherapy developed reactivation of TB several years after completing 6 months of isoniazid therapy. The estimated TB reactivation rate was 0.98 cases per 100 patient-years of follow-up in our cohort. Conclusions: Treatment for LTBI in patients with IBD treated with biologics is effective but does not eliminate the risk of reactivation.
引用
收藏
页码:2272 / 2277
页数:6
相关论文
共 50 条
  • [21] Skin anergy and latent tuberculosis in inflammatory bowel disease patients
    Herrera de Guise, C.
    Robles, V.
    Borruel, N.
    Navarro, E.
    Casellas, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S359 - S359
  • [22] Biologic treatment of Japanese patients with inflammatory bowel disease
    Jörg Mahlich
    Katsuyoshi Matsuoka
    Rosarin Sruamsiri
    BMC Gastroenterology, 18
  • [23] Biologic treatment of Japanese patients with inflammatory bowel disease
    Mahlich, Joerg
    Matsuoka, Katsuyoshi
    Sruamsiri, Rosarin
    BMC GASTROENTEROLOGY, 2018, 18
  • [24] Active tuberculosis in patients with inflammatory bowel disease after biologic therapy at university hospitals of Leicester
    Nigam, Gaurav
    Davies, Paul
    Dhiman, Paula
    Estcourt, Lise
    Grant-Casey, John
    Hearnsha, Sarah
    Jairath, Vipul
    Kumar, Bhaskar
    Leithead, Joanna
    Murphy, Mike
    Oakland, Kate
    Ratcliff, Elizabeth
    Stanley, Adrian J.
    Travis, Simon
    Uberoi, Raman
    Douds, Andy
    GUT, 2023, 72 (SUPPL_2) : A78 - A79
  • [25] Biologic Therapy in Inflammatory Bowel Disease
    Theede, Klaus
    Dahlerup, Jens Frederik
    Fallingborg, Jan
    Hvas, Christian Lodberg
    Kjeldsen, Jens
    Munck, Lars Kristian
    Nordgaard-Lassen, Inge
    DANISH MEDICAL JOURNAL, 2013, 60 (06):
  • [26] IMPROVING TUBERCULOSIS RE SCREENING IN INFLAMMATORY BOWEL DISEASE PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE CENTER QUALITY IMPROVEMENT INITIATIVE.
    Drevno, David
    Hickok, Sherry
    Ali, Sabina
    GASTROENTEROLOGY, 2020, 158 (03) : S84 - S84
  • [27] Biologic therapy of inflammatory bowel disease
    Sandborn, WJ
    Targan, SR
    GASTROENTEROLOGY, 2002, 122 (06) : 1592 - 1608
  • [28] Biologic therapy for inflammatory bowel disease
    Ardizzone, S
    Porro, GB
    DRUGS, 2005, 65 (16) : 2253 - 2286
  • [29] Biologic Therapy for Inflammatory Bowel Disease
    Sandro Ardizzone
    Gabriele Bianchi Porro
    Drugs, 2005, 65 : 2253 - 2286
  • [30] Biologic therapy of inflammatory bowel disease
    Baumgart, DC
    Wiedenmann, B
    Dignass, AU
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (10): : 1017 - 1032